Advertisement
Advertisement
U.S. Markets open in 9 hrs 27 mins
Advertisement
Advertisement
Advertisement
Advertisement

Global Blood Therapeutics, Inc. (GBT)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
30.86-0.71 (-2.25%)
At close: 4:00PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close31.57
Open31.48
Bid28.01 x 900
Ask31.33 x 1200
Day's Range30.74 - 32.10
52 Week Range25.11 - 63.03
Volume979,419
Avg. Volume1,175,785
Market Cap1.922B
Beta (5Y Monthly)1.08
PE Ratio (TTM)N/A
EPS (TTM)-4.05
Earnings DateNov 03, 2021 - Nov 08, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est72.47
  • Simply Wall St.

    Investors bid Global Blood Therapeutics (NASDAQ:GBT) up US$209m despite increasing losses YoY, taking five-year CAGR to 11%

    It hasn't been the best quarter for Global Blood Therapeutics, Inc. ( NASDAQ:GBT ) shareholders, since the share price...

  • TipRanks

    Investing in These 2 Stocks Could Double Your Money, Say Analysts

    Investors are constantly searching for the next big winner. We mean the stocks that are on track to see explosive growth, handsomely rewarding the investors that managed to get onboard at the right time. But how are investors supposed to know when it’s time to snap up the right stock? When first approaching this task, investors will often turn to names during or on the heels of an impressive rally. However, Wall Street analysts note that this isn’t always the best move. Instead, the Street’s sea

  • Benzinga

    See Why Jefferies Sees Massive Upside In Global Blood Therapeutics

    Jefferies initiated coverage of Global Blood Therapeutics Inc (NASDAQ: GBT) with a Buy rating and $68 price target. The analyst sees an upside of almost 145%. Oxbryta's implied sickle cell disease (SCD) market share is only 5%-6% at the stock's current valuation. Still, analyst Akash Tewari sees a 22% share and models $1.1 billion in peak sales for the drug in that indication. Related: Global Blood's Sickle Cell Medicine Under FDA Review For Expanded Use. Meanwhile, Tewari calls GBT601 "the most

Advertisement
Advertisement